Analysis of site-specific glycosylation in recombinant human follistatin expressed in Chinese hamster ovary cells
Introduction
Follistatin (FS), a glycoprotein, was first discovered in ovarian follicular fluid as an inhibitor of pituitary follicle-stimulating hormone secretion [1], [2]. Subsequent studies have revealed that FS can bind to activins and neutralize their biological activities [3], [4]. Activins are members of the transforming growth factor-β superfamily, and they play important roles in the regulation of cell growth and in the differentiation processes that lead to morphogenesis in early vertebrate development [5], [6]. Since FS and activins are broadly distributed, they are not confined solely to tissues associated with reproduction [7].
FS is present in heterogeneous forms [8]. The FS gene consists of 315 amino acids, and it includes six exons (Fig. 1); alternative splicing can generate two isoforms, i.e. a 315-amino-acid protein (the full-length form, FS315) and a 288-amino-acid protein (the carboxy-truncated form, FS288) [9]. The activin-neutralizing activity of FS288 is higher than that of FS315 [10], [11], which appears to correlate with their heparin/heparan sulfate proteoglycan-binding abilities [12]. The heterogeneity of FS is also due to diverse glycosylation. FS has two potential N-glycosylation sites (Asn95 and Asn259). Oligosaccharides are generally known to play important roles in defining the properties of glycoproteins such as their biological activity, immunogenicity, pharmacokinetics, solubility, and protease resistance [13], [14]. Glycosylation on FS is also likely to exert an effect on activin-neutralizing activity; however, neither structure of the N-linked oligosaccharides in FS, nor their physiological roles, have been clarified due to the limited availability of these oligosaccharides.
The aim of this study was to elucidate the glycosylation of FS. We previously developed an oligosaccharide profiling method using liquid chromatography/mass spectrometry (LC/MS) equipped with a graphitized carbon column (GCC) [15], [16], [17], [18], [19], [20], [21], [22]. Recently, we demonstrated a procedure for facilitating the structural analysis of glycoproteins [16]. Carbohydrate profiles and site-specific glycosylations can be characterized by the GCC-LC/MS method, followed by mass spectrometric peptide/glycopeptide mapping. We used this method to demonstrate here the carbohydrate heterogeneity and the site-specific N-linked oligosaccharide structures in recombinant human FS288 (rhFS) produced in Chinese hamster ovary (CHO) cells, in which a sufficient amount of FS could be expressed.
Section snippets
Materials
Human FS315 cDNA and recombinant human activin A were kindly provided by Dr. Yuzuru Eto (Ajinomoto Co., Inc., Kawasaki, Japan). CHO cells were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). Mammalian expression vector pcDNA3.1/Hygro was purchased from Invitrogen (Carlsbad, CA, USA). LipofectAMINE plus reagent, Ham's F12 medium, fetal calf serum (FCS) and hygromycin were purchased from Life Technologies Inc. (Rockville, MD, USA). Pellicon XL membrane and Immobilon-P
Heterogeneity of rhFS
The carbohydrate heterogeneity of rhFS was analyzed by SDS-PAGE with and without PNGaseF digestion. The intact rhFS migrated as bands of an apparent molecular mass of 32 kDa and 33–36 kDa under non-reducing conditions (Fig. 2A, lane 1). PNGaseF digestion resulted in the disappearance of the multiple bands at 33–36 kDa with increases in the 32-kDa band (Fig. 2A, lane 2). These results suggest that the 32 kDa band and higher molecular weight bands are the non-glycosylated FS and the glycosylated FS
Discussion
The aim of the present study was to analyze the distribution of the glycoforms and the carbohydrate structures of rhFS. Previous study of FS isolated from porcine ovary has shown that porcine FS exists in six isoforms, due to alternative splicing and the site occupancy of N-linked oligosaccharides [8]. In this study, we used rhFS288 to eliminate the heterogeneity due to alternative splicing. The results of SDS-PAGE and MALDI-TOF MS revealed the presence of both non-glycosylated and glycosylated
Acknowledgements
We thank Dr. Y. Eto (Ajinomoto Co., Inc.) for providing the human FS315 cDNA. This work was supported by a grant-in-aid for the Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation.
References (28)
- et al.
The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin
Biochem Biophys Res Commun
(1987) - et al.
Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell
J Biol Chem
(1993) Follistatin
Int J Biochem Cell Biol
(1998)- et al.
The heparin binding site of follistatin is involved in its interaction with activin
Biochem Biophys Res Commun
(1995) - et al.
A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate
J Biol Chem
(1997) - et al.
Analysis of carbohydrate heterogeneity in a glycoprotein using liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry
Anal Biochem
(1999) - et al.
Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin
Anal Biochem
(2000) - et al.
Usefulness of sugar mapping by liquid chromatography/mass spectrometry in comparability assessments of glycoprotein products
Biologicals
(2002) - et al.
Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography–electrospray ionization mass spectrometry
J Chromatogr A
(2001) - et al.
Usefulness of glycopeptide mapping by liquid chromatography/mass spectrometry in comparability assessment of glycoprotein products
Biologicals
(2002)